Published in PLoS One on September 18, 2012
Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment. PLoS One (2015) 1.38
The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem (2013) 0.93
Kinin B1 and B2 receptor deficiency protects against obesity induced by a high-fat diet and improves glucose tolerance in mice. Diabetes Metab Syndr Obes (2015) 0.76
Cigarette Smoking-Induced Cardiac Hypertrophy, Vascular Inflammation and Injury Are Attenuated by Antioxidant Supplementation in an Animal Model. Front Pharmacol (2016) 0.75
Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment. PLoS One (2014) 0.75
Retracted Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes. Am J Physiol Renal Physiol (2015) 0.75
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int (1995) 4.35
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes (2002) 3.00
The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab (2008) 2.34
Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes (2009) 1.87
The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes (2002) 1.79
A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol (2006) 1.54
Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol (2010) 1.51
Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A (2004) 1.45
Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol (2010) 1.43
Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A (2010) 1.26
Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol (2010) 1.22
The podocyte in diabetic kidney disease. ScientificWorldJournal (2009) 1.21
Advanced glycation end-products and the kidney. Eur J Clin Invest (2010) 1.19
Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes (1997) 1.11
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. Am J Cardiol (2008) 1.11
Complications of IgA nephropathy in a non-insulin-dependent diabetes model, the Akita mouse. Tohoku J Exp Med (2002) 1.10
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes (2003) 1.06
Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl (2002) 1.00
Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens (2001) 0.98
Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol (2007) 0.96
Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol (2009) 0.94
Effects of B1 and B2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol (1996) 0.91
Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Can J Physiol Pharmacol (2002) 0.90
Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Kidney Int (2007) 0.88
Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes (1995) 0.88
Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus. Relationship to glomerular and tubular function. Diabetologia (1992) 0.87
Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol (2005) 0.86
Molecular determinants of LPS-induced acute renal inflammation: Implication of the kinin B1 receptor. Biochem Biophys Res Commun (2009) 0.85
Mechanisms involved in the genesis of diabetic nephropathy. Curr Diabetes Rev (2010) 0.85
Additive renoprotective effects of B2-kinin receptor blocker and PPAR-γ agonist in uninephrectomized db/db mice. Lab Invest (2011) 0.84
Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol (2002) 0.81
Renal kallikrein and hemodynamic abnormalities of diabetic kidney. Diabetes (1990) 0.81
Association of the human bradykinin B2 receptor gene with chronic renal failure. Mol Diagn (2004) 0.80
Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes. Biol Chem (2006) 0.79
Modulation of renal inflammation: therapeutic strategies. Saudi J Kidney Dis Transpl (2008) 0.78
Chemokines and renal inflammation. Nephrologie (1999) 0.78
Expression analysis using oligonucleotide microarrays in mice lacking bradykinin type 2 receptors. Hypertension (2001) 0.77
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes (2005) 3.10
Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol (2007) 1.69
Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol (2003) 1.56
Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. Kidney Int (2004) 1.53
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol (2006) 1.51
Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. J Pediatr Hematol Oncol (2006) 1.45
Nox4 NAD(P)H oxidase mediates Src-dependent tyrosine phosphorylation of PDK-1 in response to angiotensin II: role in mesangial cell hypertrophy and fibronectin expression. J Biol Chem (2008) 1.43
Leptin and renal disease. Am J Kidney Dis (2002) 1.42
Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol (2007) 1.38
Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun (2002) 1.35
Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci (2010) 1.28
Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes (2005) 1.25
Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int (2002) 1.24
Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood (2006) 1.24
Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. Diabetes (2004) 1.19
Vascular endothelial growth factor and diabetic nephropathy. Curr Diab Rep (2008) 1.13
Leptin and renal fibrosis. Contrib Nephrol (2006) 1.12
Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun (2003) 1.08
Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors. J Biol Chem (2006) 1.02
Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant (2005) 1.01
The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. J Am Soc Nephrol (2008) 0.97
Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol (2007) 0.96
The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J Biol Chem (2007) 0.96
Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem (2010) 0.95
The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol (2010) 0.95
Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells. Am J Physiol Heart Circ Physiol (2005) 0.94
The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem (2013) 0.93
Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med (2006) 0.93
Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. J Med Genet (2010) 0.92
Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol (2013) 0.92
Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. Kidney Int (2005) 0.91
Gliotypic neural stem cells transiently adopt tumorigenic properties during normal differentiation. Stem Cells (2009) 0.90
Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. ASN Neuro (2011) 0.89
Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis (2006) 0.88
Identification of proteins sensitive to thermal stress in human neuroblastoma and glioma cell lines. PLoS One (2012) 0.88
20-HETE and EETs in diabetic nephropathy: a novel mechanistic pathway. PLoS One (2013) 0.87
Cultured tubule cells from TGF-beta1 null mice exhibit impaired hypertrophy and fibronectin expression in high glucose. Kidney Int (2004) 0.87
Proteomics studies of traumatic brain injury. Int Rev Neurobiol (2004) 0.87
Combining biochemical and imaging markers to improve diagnosis and characterization of mild traumatic brain injury in the acute setting: results from a pilot study. PLoS One (2013) 0.86
Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol (2005) 0.86
Overpressure blast-wave induced brain injury elevates oxidative stress in the hypothalamus and catecholamine biosynthesis in the rat adrenal medulla. Neurosci Lett (2013) 0.85
Biomarkers track damage after graded injury severity in a rat model of penetrating brain injury. J Neurotrauma (2013) 0.85
Systems biology and theranostic approach to drug discovery and development to treat traumatic brain injury. Methods Mol Biol (2010) 0.85
The challenge of mild traumatic brain injury: role of biochemical markers in diagnosis of brain damage. Med Res Rev (2013) 0.84
Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther (2002) 0.84
Mechanisms of angiotensin II-induced expression of B2 kinin receptors. Am J Physiol Heart Circ Physiol (2004) 0.83
Evidence for low-density lipoprotein-induced expression of connective tissue growth factor in mesangial cells. Kidney Int (2005) 0.82
Phospholipase C and protein kinase C-β 2 mediate insulin-like growth factor II-dependent sphingosine kinase 1 activation. Mol Endocrinol (2011) 0.82
A 5-year survey of biopsy proven kidney diseases in Lebanon: significant variation in prevalence of primary glomerular diseases by age, population structure and consanguinity. Nephrol Dial Transplant (2010) 0.81
Proteomic analysis and brain-specific systems biology in a rodent model of penetrating ballistic-like brain injury. Electrophoresis (2012) 0.81
The cardiorenal syndrome in diabetes mellitus. Diabetes Res Clin Pract (2010) 0.81
Diabetes modulates the expression of glomerular kinin receptors. Int Immunopharmacol (2002) 0.81
Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis (2012) 0.81
Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside. Transl Stroke Res (2011) 0.81
Role of reactive oxygen species in bradykinin-induced proliferation of vascular smooth muscle cells. Biol Res (2004) 0.81
Ceacam1 deletion causes vascular alterations in large vessels. Am J Physiol Endocrinol Metab (2013) 0.81
Taurine intestinal absorption and renal excretion test in diabetic patients: a pilot study. Diabetes Care (2007) 0.80
Different expression of ubiquitin C-terminal hydrolase-L1 and αII-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis. Brain Res (2013) 0.80
Evidence for prostacyclin and cAMP upregulation by bradykinin and insulin-like growth factor 1 in vascular smooth muscle cells. J Recept Signal Transduct Res (2010) 0.79
Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes (2015) 0.78
Emerging therapies for diabetic nephropathy patients: beyond blockade of the Renin-Angiotensin system. Nephron Extra (2012) 0.78
Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells. Mol Endocrinol (2012) 0.78
Epidemiology and clinical characteristics of traumatic brain injury in Lebanon: A systematic review. Medicine (Baltimore) (2016) 0.78
Some immunological aspects of patients with rhinitis in Lebanon. Immunopharmacol Immunotoxicol (2002) 0.78
Angiogenic factors. Contrib Nephrol (2011) 0.78
Slope Estimation of Covariates that Influence Renal Outcome following Renal Transplant Adjusting for Informative Right Censoring. J Appl Stat (2015) 0.78
Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1. Kidney Int (2002) 0.78
Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. Am J Physiol Renal Physiol (2013) 0.77
Pilot study using proteomics to identify predictive biomarkers of necrotizing enterocolitis from buccal swabs in very low birth weight infants. Neonatology (2013) 0.77
Circulating immune complexes and complement C3 and C4 levels in a selected group of patients with rhinitis in Lebanon. Clin Mol Allergy (2004) 0.77
Proteomics studies in inner ear disorders: pathophysiology and biomarkers. Expert Rev Proteomics (2015) 0.76
Regulation of inducible class II MHC, costimulatory molecules, and cytokine expression in TGF-beta1 knockout renal epithelial cells: effect of exogenous TGF-beta1. Exp Nephrol (2002) 0.76
Minor and repetitive head injury. Adv Tech Stand Neurosurg (2015) 0.76
Joint Modeling of Covariates and Censoring Process Assuming Non-Constant Dropout Hazard. Stat Methods Appt (2015) 0.75
Correction: Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment. PLoS One (2015) 0.75
Why should an angiogenic factor modulate tubular structure in diabetic nephropathy? Some answers, more questions. Kidney Int (2003) 0.75
Steroid treatment of drug-induced acute interstitial nephritis. Kidney Int (2008) 0.75
Utilization of a radioimmunoassay to detect the generation of Arg-Pro-Pro-Gly-Phe, a stable endproduct of bradykinin metabolism (from cultured rat aortic smooth muscle cells exposed to bradykinin). Int Immunopharmacol (2002) 0.75
Glycosylation Changes in Brain Cancer. ACS Chem Neurosci (2017) 0.75
Identification of novel targets of cephaloridine in rabbit renal proximal tubules synthesizing glutamine from alanine. Arch Toxicol (2005) 0.75
Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells. J Recept Signal Transduct Res (2014) 0.75
End stage renal disease in six patients with beta-thalassemia intermedia. Blood Cells Mol Dis (2013) 0.75
Proteome profiling in the aorta and kidney of type 1 diabetic rats. PLoS One (2017) 0.75